Morgan Stanley’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $573M | Sell |
6,339,368
-721,508
| -10% | -$60.4M | 0.03% | 514 |
|
|
2026
Q1 | $565M | Sell |
7,060,876
-253,416
| -3% | -$20.9M | 0.03% | 488 |
|
|
2025
Q4 | $624M | Buy |
7,314,292
+804,942
| +12% | +$66.1M | 0.04% | 455 |
|
|
2025
Q3 | $506M | Sell |
6,509,350
-985,242
| -13% | -$77M | 0.03% | 510 |
|
|
2025
Q2 | $586M | Buy |
7,494,592
+145,348
| +2% | +$10.8M | 0.04% | 452 |
|
|
2025
Q1 | $533M | Buy |
7,349,244
+212,593
| +3% | +$15.2M | 0.04% | 443 |
|
|
2024
Q4 | $528M | Buy |
7,136,651
+1,415,889
| +25% | +$99.1M | 0.04% | 453 |
|
|
2024
Q3 | $378M | Sell |
5,720,762
-829,710
| -13% | -$60.3M | 0.03% | 566 |
|
|
2024
Q2 | $605M | Buy |
6,550,472
+371,410
| +6% | +$32.9M | 0.05% | 368 |
|
|
2024
Q1 | $590M | Buy |
6,179,062
+70,901
| +1% | +$5.96M | 0.05% | 380 |
|
|
2023
Q4 | $466M | Sell |
6,108,161
-985,267
| -14% | -$68.6M | 0.04% | 427 |
|
|
2023
Q3 | $491M | Sell |
7,093,428
-592,418
| -8% | -$47.6M | 0.05% | 360 |
|
|
2023
Q2 | $725M | Buy |
7,685,846
+844,484
| +12% | +$73.4M | 0.07% | 257 |
|
|
2023
Q1 | $566M | Sell |
6,841,362
-342,452
| -5% | -$26.9M | 0.06% | 306 |
|
|
2022
Q4 | $536M | Buy |
7,183,814
+855,755
| +14% | +$66M | 0.06% | 321 |
|
|
2022
Q3 | $523M | Buy |
6,328,059
+66,704
| +1% | +$6.42M | 0.07% | 263 |
|
|
2022
Q2 | $595M | Buy |
6,261,355
+3,023,685
| +93% | +$313M | 0.08% | 245 |
|
|
2022
Q1 | $381M | Sell |
3,237,670
-457,979
| -12% | -$51.4M | 0.05% | 335 |
|
|
2021
Q4 | $479M | Buy |
3,695,649
+303,564
| +9% | +$35.4M | 0.06% | 300 |
|
|
2021
Q3 | $384M | Buy |
3,392,085
+187,879
| +6% | +$21.4M | 0.05% | 328 |
|
|
2021
Q2 | $332M | Buy |
3,204,206
+164,907
| +5% | +$15.5M | 0.04% | 376 |
|
|
2021
Q1 | $254M | Buy |
3,039,299
+221,400
| +8% | +$18.7M | 0.04% | 415 |
|
|
2020
Q4 | $257M | Buy |
2,817,899
+193,176
| +7% | +$16M | 0.04% | 391 |
|
|
2020
Q3 | $210M | Buy |
2,624,723
+162,716
| +7% | +$12.7M | 0.04% | 374 |
|
|
2020
Q2 | $170M | Buy |
2,462,007
+82,587
| +3% | +$5.87M | 0.04% | 398 |
|
|
2020
Q1 | $150M | Sell |
2,379,420
-666,663
| -22% | -$48.1M | 0.04% | 387 |
|
|
2019
Q4 | $237M | Buy |
3,046,083
+777,024
| +34% | +$60.7M | 0.06% | 329 |
|
|
2019
Q3 | $166M | Sell |
2,269,059
-741,471
| -25% | -$52.1M | 0.04% | 392 |
|
|
2019
Q2 | $185M | Buy |
3,010,530
+421,599
| +16% | +$25.5M | 0.05% | 363 |
|
|
2019
Q1 | $165M | Sell |
2,588,931
-623,973
| -19% | -$35.6M | 0.05% | 383 |
|
|
2018
Q4 | $164M | Buy |
3,212,904
+80,577
| +3% | +$4.08M | 0.05% | 364 |
|
|
2018
Q3 | $182M | Sell |
3,132,327
-856,047
| -21% | -$41.9M | 0.05% | 381 |
|
|
2018
Q2 | $194M | Buy |
3,988,374
+1,107,081
| +38% | +$51.7M | 0.05% | 349 |
|
|
2018
Q1 | $134M | Sell |
2,881,293
-1,014,042
| -26% | -$44M | 0.04% | 462 |
|
|
2017
Q4 | $146M | Buy |
3,895,335
+427,107
| +12% | +$15.7M | 0.04% | 450 |
|
|
2017
Q3 | $126M | Buy |
3,468,228
+180,654
| +5% | +$6.89M | 0.04% | 460 |
|
|
2017
Q2 | $130M | Sell |
3,287,574
-1,167,600
| -26% | -$42.6M | 0.04% | 460 |
|
|
2017
Q1 | $140M | Buy |
4,455,174
+998,013
| +29% | +$31.2M | 0.04% | 434 |
|
|
2016
Q4 | $108M | Sell |
3,457,161
-1,959,510
| -36% | -$63.5M | 0.04% | 508 |
|
|
2016
Q3 | $218M | Sell |
5,416,671
-911,775
| -14% | -$34.3M | 0.07% | 293 |
|
|
2016
Q2 | $210M | Buy |
6,328,446
+1,240,776
| +24% | +$42.5M | 0.08% | 289 |
|
|
2016
Q1 | $150M | Buy |
5,087,670
+633,423
| +14% | +$17.5M | 0.06% | 356 |
|
|
2015
Q4 | $117M | Buy |
4,454,247
+1,337,049
| +43% | +$34.7M | 0.04% | 433 |
|
|
2015
Q3 | $73.9M | Buy |
3,117,198
+955,608
| +44% | +$23.1M | 0.03% | 598 |
|
|
2015
Q2 | $51.3M | Sell |
2,161,590
-1,240,074
| -36% | -$28M | 0.02% | 848 |
|
|
2015
Q1 | $80.8M | Sell |
3,401,664
-808,278
| -19% | -$18.1M | 0.03% | 586 |
|
|
2014
Q4 | $89.4M | Buy |
4,209,942
+2,109,324
| +100% | +$42.4M | 0.03% | 556 |
|
|
2014
Q3 | $35.8M | Buy |
2,100,618
+542,364
| +35% | +$8.56M | 0.01% | 1005 |
|
|
2014
Q2 | $22.3M | Buy |
1,558,254
+238,824
| +18% | +$3.24M | 0.01% | 1343 |
|
|
2014
Q1 | $16.3M | Sell |
1,319,430
-48,210
| -4% | -$556K | 0.01% | 1542 |
|
|
2013
Q4 | $15M | Sell |
1,367,640
-784,200
| -36% | -$8.84M | 0.01% | 1589 |
|
|
2013
Q3 | $25M | Buy |
2,151,840
+698,328
| +48% | +$8.17M | 0.01% | 1060 |
|
|
2013
Q2 | $16.3M | Buy |
+1,453,512
| New | +$17.2M | 0.01% | 1321 |
|
Other funds holding EW
Morgan Stanley's EW Position: Q2 2026 in Review
Morgan Stanley reduced its Edwards Lifesciences (EW) stake by 10% in Q2 2026, selling an estimated $60.4M and leaving 6,339,368 shares worth $573M. The position accounts for 0.03% of the portfolio, ranked #514.
Morgan Stanley first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $725M in Q2 2023. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Morgan Stanley held 6,339,368 shares of Edwards Lifesciences worth $573M as of Q2 2026.
- Morgan Stanley sold 721,508 Edwards Lifesciences shares in Q2 2026, an estimated $60.4M.
- Edwards Lifesciences made up 0.03% of Morgan Stanley's portfolio in Q2 2026, its #514 holding.
- Morgan Stanley first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's Edwards Lifesciences position peaked at $725M in Q2 2023.
- 1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.